# Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

> **NCT06221241** · PHASE2 · UNKNOWN · sponsor: **Jemincare** · enrollment: 220 (estimated)

## Conditions studied

- Diabetic Peripheral Neuropathic Pain

## Interventions

- **DRUG:** JMKX000623
- **DRUG:** Pregabalin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06221241
- **Lead sponsor:** Jemincare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-25
- **Primary completion:** 2025-03-14
- **Final completion:** 2025-04-30
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06221241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06221241, "Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06221241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*